EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
- Country
- Belgium
- Type
- Beneficiary
- Website
- www.eortc.be
- Grants received
- 29
Funding record
- 29 grants on record
- €22,974,449.20 awarded in total
- 2008–2023 span of the record
Grants recorded here are the ones our sources publish, and the total is the sum of those. It is not a statement of this organisation's total funding.
Programmes
11 further grants are on record without a programme named by the source, or under a programme outside the largest shown here.
Frequent partners
Organisations this one has been funded alongside on two or more projects. A single shared consortium is not counted: the largest here has 195 members, and being on one list together is not a collaboration.
- THE UNIVERSITY OF MANCHESTER
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
- INSTITUT GUSTAVE ROUSSY
- MEDIZINISCHE UNIVERSITAET WIEN
- FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
- INSTITUT CURIE
- OSLO UNIVERSITETSSYKEHUS HF
- STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Calls from this organisation
No published calls from this organisation.
Grants received
- Lomustine with or without reirradiation for first progression of glioblastoma: a pragmatic randomized phase III study
- A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR PATIENTS WITH HIGH RISK RETROPERITONEAL SARCOMA
- INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL
- COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE
- Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe
- THE STRONG-AYA INITIATIVE: IMPROVING THE FUTURE OF YOUNG ADULTS WITH CANCER
- Providing cutting edge cancer research services across Europe
- Optimal treatment for patients with solid tumours in Europe through Artificial intelligence
- Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe
- European Joint Programme on Rare Diseases
- Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope
- Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106
- Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026
- Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)
- Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
Data source
© European Union, 2026. Source: CORDIS. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
Retrieved from the source on .
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.